Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Kevin Kalinsky, David M. Goldenberg et al.|New England Journal of Medicine|2019Cited by 846
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Linda T. Vahdat, Ingrid A. Mayer et al.|Journal of Clinical Oncology|2017Cited by 407
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Giuseppe Viale et al.|Cancer Discovery|2021Cited by 241
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.Otto Metzger, Ian E. Krop, Giuseppe Viale et al.|Journal of Clinical Oncology|2019Cited by 82
HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trialZheqi Li, Kornélia Polyák, Otto Metzger et al.|Journal of Clinical Investigation|2024Cited by 29